Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer

医学 中性粒细胞减少症 胃肠病学 内科学 恶心 呕吐 药代动力学 贫血 不利影响 化疗
作者
J.F. Liu,Kathleen N. Moore,Michael J. Birrer,S. Berlin,Ursula A. Matulonis,J. R. Infante,Brian M. Wolpin,Kirsten Achilles Poon,Ron Firestein,Jian Xu,Ryan Kahn,Yulei Wang,Katie Wood,Walter C. Darbonne,Mark R. Lackner,Sean K. Kelley,Xln Lu,Yoon Jeong Choi,Daniel Maslyar,Eric W. Humke
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:27 (11): 2124-2130 被引量:89
标识
DOI:10.1093/annonc/mdw401
摘要

MUC16 is a tumor-specific antigen overexpressed in ovarian (OC) and pancreatic (PC) cancers. The antibody-drug conjugate (ADC), DMUC5754A, contains the humanized anti-MUC16 monoclonal antibody conjugated to the microtubule-disrupting agent, monomethyl auristatin E (MMAE).This phase I study evaluated safety, pharmacokinetics (PK), and pharmacodynamics of DMUC5754A given every 3 weeks (Q3W, 0.3-3.2 mg/kg) or weekly (Q1W, 0.8-1.6 mg/kg) to patients with advanced recurrent platinum-resistant OC or unresectable PC. Biomarker studies were also undertaken.Patients (66 OC, 11 PC) were treated with DMUC5754A (54 Q3W, 23 Q1W). Common related adverse events (AEs) in >20% of patients (all grades) over all dose levels were fatigue, peripheral neuropathy, nausea, decreased appetite, vomiting, diarrhea, alopecia, and pyrexia in Q3W patents, and nausea, vomiting, anemia, fatigue, neutropenia, alopecia, decreased appetite, diarrhea, and hypomagnesemia in Q1W patients. Grade ≥3-related AE in ≥5% of patients included neutropenia (9%) and fatigue (7%) in Q3W patients, and neutropenia (17%), diarrhea (9%), and hyponatremia (9%) in Q1W patients. Plasma antibody-conjugated MMAE (acMMAE) and serum total antibody exhibited non-linear PK across tested doses. Minimal accumulation of acMMAE, total antibody, or unconjugated MMAE was observed. Confirmed responses (1 CR, 6 PRs) occurred in OC patients whose tumors were MUC16-positive by IHC (2+ or 3+). Two OC patients had unconfirmed PRs; six OC patients had stable disease lasting >6 months. For CA125, a cut-off of ≥70% reduction was more suitable for monitoring treatment response due to the binding and clearance of serum CA125 by MUC16 ADC. We identified circulating HE4 as a potential novel surrogate biomarker for monitoring treatment response of MUC16 ADC and other anti-MUC16 therapies in OC.DMUC5754A has an acceptable safety profile and evidence of anti-tumor activity in patients with MUC16-expressing tumors. Objective responses were only observed in MUC16-high patients, although prospective validation is required.NCT01335958.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
方勇飞发布了新的文献求助20
1秒前
taozi完成签到,获得积分10
1秒前
2秒前
虚幻秋白完成签到,获得积分20
2秒前
Hello应助LiQi采纳,获得10
2秒前
甜甜甜完成签到 ,获得积分10
4秒前
5秒前
ttong完成签到,获得积分10
5秒前
5秒前
虚幻秋白发布了新的文献求助10
6秒前
123完成签到 ,获得积分10
8秒前
8秒前
bkagyin应助海孩子采纳,获得30
11秒前
11秒前
11秒前
今后应助多情邑采纳,获得10
11秒前
李尚泽完成签到,获得积分10
12秒前
麦子发布了新的文献求助10
12秒前
LiQi完成签到,获得积分10
13秒前
好好好发布了新的文献求助10
13秒前
小蘑菇应助山楂采纳,获得10
15秒前
gogoyoco发布了新的文献求助10
15秒前
Cumin完成签到 ,获得积分10
15秒前
搜集达人应助舍予有服采纳,获得10
16秒前
16秒前
16秒前
16秒前
无花果应助rrgogo采纳,获得10
17秒前
活力的小猫咪完成签到 ,获得积分10
20秒前
幸福大白发布了新的文献求助10
21秒前
完美世界应助成就茗采纳,获得10
21秒前
YJ888发布了新的文献求助10
23秒前
云雾完成签到 ,获得积分10
24秒前
无辜忆寒完成签到,获得积分10
25秒前
科研顺利完成签到,获得积分10
25秒前
26秒前
科研通AI5应助幸福大白采纳,获得30
26秒前
29秒前
31秒前
31秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989550
求助须知:如何正确求助?哪些是违规求助? 3531774
关于积分的说明 11254747
捐赠科研通 3270278
什么是DOI,文献DOI怎么找? 1804966
邀请新用户注册赠送积分活动 882125
科研通“疑难数据库(出版商)”最低求助积分说明 809176